These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1718322)

  • 1. Estrogens and benign prostatic hyperplasia: rationale for therapy with aromatase inhibitors.
    Henderson D
    Ann Med; 1991 Aug; 23(3):201-3. PubMed ID: 1718322
    [No Abstract]   [Full Text] [Related]  

  • 2. The function and the role of aromatase inhibitors in the treatment of BPH.
    el Etreby MF; Habenicht UF
    Prog Clin Biol Res; 1994; 386():209-30. PubMed ID: 7528389
    [No Abstract]   [Full Text] [Related]  

  • 3. Aromatase inhibitors: their biochemistry and clinical potential.
    Henderson D
    J Steroid Biochem; 1987; 27(4-6):905-14. PubMed ID: 2447395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aromatase inhibitors in the medical treatment of benign prostatic hypertrophy].
    Tunn UW; Goldschmidt AJ
    J Urol (Paris); 1993; 99(6):307. PubMed ID: 7516374
    [No Abstract]   [Full Text] [Related]  

  • 5. Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies.
    Habenicht UF; el Etreby MF
    J Androl; 1991; 12(6):395-402. PubMed ID: 1722796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aromatase inhibitors and benign prostatic hyperplasia.
    Henderson D; Habenicht UF; Nishino Y; Kerb U; el Etreby MF
    J Steroid Biochem; 1986 Nov; 25(5B):867-76. PubMed ID: 2433507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. The Schering 90.062 Study Group.
    Gingell JC; Knönagel H; Kurth KH; Tunn UW
    J Urol; 1995 Aug; 154(2 Pt 1):399-401. PubMed ID: 7541854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogens and benign prostatic hyperplasia: the basis for aromatase inhibitor therapy.
    Henderson D; Habenicht UF; Nishino Y; el Etreby MF
    Steroids; 1987; 50(1-3):219-33. PubMed ID: 2460976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors.
    Habenicht UF; Tunn UW; Senge T; Schröder FH; Schweikert HU; Bartsch G; el Etreby MF
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):557-63. PubMed ID: 7682837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a model for the induction of estrogen-related prostatic hyperplasia in the dog and its response to the aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione: preliminary results.
    Habenicht UF; Schwarz K; Schweikert HU; Neumann F; el Etreby MF
    Prostate; 1986; 8(2):181-94. PubMed ID: 2419882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine therapy for benign prostatic hyperplasia in the 90's.
    Ekman P
    J Urol (Paris); 1995; 101(1):22-5. PubMed ID: 7545721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atamestane: an aromatase inhibitor for the treatment of benign prostatic hyperplasia. A short review.
    el Etreby MF
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):565-72. PubMed ID: 7682838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical therapy for benign prostatic hyperplasia.
    Keetch DW; Andriole GL
    AJR Am J Roentgenol; 1995 Jan; 164(1):11-5; discussion 16-7. PubMed ID: 7527995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Physiopathological aspects of the treatment of benign prostatic hypertrophy. Role of prostatic stroma and estrogens].
    Solè-Balcells F
    J Urol (Paris); 1993; 99(6):303-6. PubMed ID: 7516373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of estrogens in human benign prostatic hyperplasia.
    Sciarra F; Toscano V
    Arch Androl; 2000; 44(3):213-20. PubMed ID: 10864369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of estrogen deprivation on human benign prostatic hyperplasia.
    Schweikert HU; Tunn UW; Habenicht UF; Arnold J; Senge T; Schulze H; Schröder FH; Blom JH; Ennemoser O; Horniger W
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):573-6. PubMed ID: 7682839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia.
    el Etreby MF; Nishino Y; Habenicht UF; Henderson D
    J Androl; 1991; 12(6):403-14. PubMed ID: 1722797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group.
    Radlmaier A; Eickenberg HU; Fletcher MS; Fourcade RO; Reis Santos JM; van Aubel OG; Bono AV
    Prostate; 1996 Oct; 29(4):199-208. PubMed ID: 8876703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatase inhibition in the dog. II. Effect on growth, function, and pathology of the prostate.
    Oesterling JE; Juniewicz PE; Walters JR; Strandberg JD; Steele RE; Ewing LL; Coffey DS
    J Urol; 1988 Apr; 139(4):832-9. PubMed ID: 2451040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergic inhibitory effects of the aromatase inhibitor 1-methyl-androsta-1, 4-diene-3, 17-dione and the antiandrogen cyproterone acetate on androstenedione-induced hyperplastic effects in the prostates of castrated dogs.
    Habenicht UF; el Etreby MF
    Prostate; 1987; 11(2):133-43. PubMed ID: 2444953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.